Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.
BioVaxys Technology Corp. (OTCQB: BVAXF) is a clinical-stage biopharmaceutical company whose news flow centers on its DPX™ immune-educating platform, oncology vaccine programs, and licensing activities. Company releases describe DPX as a non-systemic antigen delivery technology used to generate targeted and persistent immune responses, with applications in cancer, infectious disease, and antigen desensitization.
Investors following BVAXF news can expect updates on clinical studies of maveropepimut-S (MVP-S) in advanced relapsed-refractory diffuse large B cell lymphoma and platinum-resistant ovarian cancer, as well as early-stage work in non-muscle invasive bladder cancer and HR+/HER2- breast cancer. News items also highlight DPX+SurMAGE, a dual-targeted immunotherapy for bladder cancer, and DPX-based vaccines such as DPX-RSV and DPX+rPA for anthrax.
BioVaxys regularly reports on collaborations and licensing agreements that leverage its lipid-based technologies. Examples include licensing to SpayVac-for-Wildlife, Inc. for single-dose immunocontraceptive vaccines in wildlife and aquaculture, and to Zoetis Inc. for animal health applications. The company also issues updates on research collaborations, such as combining DPX with Sona Nanotech’s Targeted Hyperthermia Therapy™ and exploring DPX as a carrier for mRNA vaccines.
In addition to scientific and clinical developments, BVAXF news covers corporate actions such as amendments to its asset purchase agreement for the DPX portfolio, share consolidation on the Canadian Securities Exchange, and financing-related milestones. For readers tracking BVAXF, this news page aggregates these disclosures so they can monitor progress of the DPX platform, pipeline evolution, and key partnership developments over time.
BioVaxys Technology Corp announces presentation by Co-Founder and Chief Medical Officer David Berd at the World Vaccine & Immunotherapy Congress in San Diego from November 30-December 2, 2021. Dr. Berd will discuss the potential of haptenized autologous tumor cell vaccines for cancer treatment and the advancement of haptenized viral antigens against SARS-CoV-2 and other viruses. The presentation is scheduled for December 1, 2021 at 17:10 PST. BioVaxys is advancing its platform for viral and oncology vaccines, including a SARS-CoV-2 vaccine aimed at clinical trials.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced positive results from its in vivo study demonstrating the safety and tolerability of CoviDTH, a diagnostic tool for T-cell response to SARS-CoV-2. Conducted with Inotiv, the study showed no adverse effects at doses significantly higher than human levels, except for mild localized redness. The FDA indicated that animal toxicity studies were not required, allowing BioVaxys to move forward with a combined Phase I/II clinical development program. CoviDTH is noted as a cost-effective, point-of-care diagnostic tool validated by recent clinical studies.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced a presentation of preclinical data for its SARS-CoV-2 vaccine candidate, BVX-0320, at the ISIRV-WHO Virtual Congress on October 19-21, 2021. The poster, authored by Chief Medical Officer David Berd, showcases significant antibody and T cell responses in a murine model. The company is advancing its haptenized viral protein technology and preparing for a clinical trial of its cancer vaccine. BioVaxys emphasizes that it does not claim ability to treat SARS-CoV-2 at this time.
BioVaxys Technology Corp. has initiated an in vivo animal toxicology study of its diagnostic tool, CoviDTH, in conjunction with an upcoming IND submission. The study, carried out by Inotiv, Inc., will assess the safety and toxicity of the SARS-CoV-2 s-protein used in CoviDTH. Although the FDA indicated that animal toxicity studies were not required, BioVaxys believes this data could be useful. CoviDTH is designed to evaluate T-cell immune responses in vaccinated or exposed individuals, reinforcing its potential as a low-cost, point-of-care diagnostic.
BioVaxys Technology Corp. announced the engagement of 6 Degrees, a communications firm, to enhance its strategic communications, public and media relations, and social media efforts. The President & COO, Kenneth Kovan, stated that this decision aligns with BioVaxys's growth and aims to increase public awareness. BioVaxys is focused on developing vaccines and diagnostics for viral and oncology applications, including a SARS-CoV-2 vaccine and cancer therapies. The company holds two US patents related to its cancer vaccine and has pending applications for its COVID-19 vaccine technologies.
BioVaxys Technology Corp. announced on September 20, 2021, that it has engaged 6 Degrees, a life sciences communications firm, to enhance its strategic communications and public relations efforts. The partnership aims to improve BioVaxys's visibility as the company advances its oncology and viral vaccine platforms, including a SARS-CoV-2 vaccine and a cell vaccine for ovarian cancer. BioVaxys holds two U.S. patents related to its cancer vaccine and is pursuing additional patents for its COVID-19 technologies.
BioVaxys Technology Corp. announced significant progress with cancer vaccine BVX-0918A, as manufacturing partner Bio Elpida in Lyon, France, completes key milestones in its development. The process now transitions to the next phase, focusing on a Quality by Design approach while preparing for GMP manufacturing. The vaccine aims to begin a Phase I clinical trial in Spain early next year. CEO Ken Kovan highlighted this achievement as a testament to their manufacturing partners' capabilities and a vital step for BioVaxys in advancing its oncology solutions.
BioVaxys Technology Corp. announced that WuXi Biologics has successfully synthesized recombinant SARS-CoV-2 s-protein for its COVID-19 vaccine candidate BVX-0320 and the CoviDTH immunodiagnostic product. Both products are set for clinical trials, with an IND submission to the FDA for CoviDTH underway. The company has confirmed high yields of the protein, essential for clinical studies, while the FDA noted that a preclinical animal toxicity study is not mandatory for IND submission. BioVaxys continues this study for additional data.
BioVaxys Technology Corp. announced that Dr. Yvelise Barrios presented a study on the durability of T-cell responses to SARS-CoV-2 at the European Congress of Immunology. The study indicates that the DTH response, the basis for BioVaxys' CoviDTH diagnostic tool, can last over a year post-infection. Results showed significant DTH responses in two patients at both six and twelve months. BioVaxys aims to advance its vaccine development, awaiting an IND for a planned Phase I/II study in the US. The DTH test could serve as a routine method for monitoring T-cell immunity.
BioVaxys Technology Corp. has successfully closed the second tranche of its non-brokered private placement, raising approximately $1,176,880 by issuing 5,349,455 units at $0.22 each. Combined with the first tranche completed on July 14, 2021, total proceeds amount to $2,015,555. Each unit comprises one common share and a warrant exercisable at $0.50 for 30 months. The company plans to utilize these funds for research and development and working capital, subject to a four-month hold period for the issued securities.
FAQ
What is the current stock price of Biovaxys Technol (BVAXF)?
What is the market cap of Biovaxys Technol (BVAXF)?
